Seven (53·8%) patients received tafenoquine, and causes of death were electric shock, cancer, COVID-19, hypertension, external cause (injury), and two with undetermined cause: one died at 329 days after treatment (G6PD status unknown) and one at 40 days after treatment (G6PD normal). The gene discussed is G6PD; the disease is COVID-19.